Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

NCT05341947 is registered in ClinicalTrials.gov with Jeremy Rudnick, M.D as lead sponsor.

NCT NCT05341947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05341947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Lead sponsor
Jeremy Rudnick, M.D
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2026
Completion date
December 31, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma